Table 1

Baseline characteristics and laboratory findings according to BMI groupsa
Total n = 4131 Normal weight n = 1395 Overweight n = 1970 Obese n = 766 p-valueb
Demographic characteristics
Male sex, n (%) 2989 (72.4) 959 (68.7) 1517 (77.0) 513 (67.0) <0.001
Age (years)c 62 (10) 63 (11) 61 (10) 60 (10) <0.001
Clinical parameters
Systolic blood pressure (mmHg) 141 (20.7) 139 (21.0) 142 (20.6) 143 (20.3) <0.001
Diastolic blood pressure (mmHg) 81.3 (10.4) 79.3 (10.3) 82.0 (10.1) 83.3 (10.7) <0.001
Left ventricular ejection fraction (%) 64.0 (11.3) 63.7 (11.9) 64.4 (10.7) 63.6 (11.8) 0.08
Cardiovascular risk factors, n (%)
Diabetesd 496 (12.0) 123 (8.8) 209 (10.6) 164 (21.4) <0.001
Current smokere 1061 (25.7) 417 (29.9) 469 (23.9) 175 (22.9) <0.001
Ex smokerf 1933 (46.9) 571 (40.6) 975 (49.6) 387 (50.7) <0.001
Family history of coronary heart diseaseg 1253 (31.1) 417 (30.8) 573 (29.7) 263 (35.1) 0.02
Cardiovascular history, n (%)
Previous acute myocardial infarction 1670 (40.4) 564 (40.4) 784 (39.8) 322 (42.0) 0.56
Previous cerebrovascular disease 286 (6.9) 100 (7.2) 128 (6.5) 58 (7.6) 0.55
Previous peripheral vascular arterial disease 371 (9.0) 153 (11.0) 148 (7.5) 70 (9.1) <0.01
Previous percutaneous coronary intervention 794 (19.2) 250 (17.9) 396 (20.1) 148 (19.3) 0.29
Previous coronary artery bypass graft surgery 477 (11.5) 150 (10.8) 238 (12.1) 89 (11.6) 0.49
Extent of coronary artery disease at baseline as assessed by coronary angiography, n (%)
No significant coronary artery disease 1030 (24.9) 367 (26.3) 467 (23.7) 196 (25.6) 0.21
1-vessel disease 958 (23.2) 306 (21.9) 482 (24.5) 170 (22.2) 0.18
2-vessel disease 923 (22.3) 308 (22.1) 440 (22.3) 175 (22.8) 0.92
3-vesseldisease 1220 (29.5) 414 (29.7) 581 (29.5) 225 (29.4) 0.99
Comorbidity at baseline, n (%)
Pulmonary disease 367 (8.9) 139 (10.0) 140 (7.1) 88 (11.5) <0.001
Cancer 4 (0.1) 2 (0.1) 1 (0.1) 1 (0.1) 0.66
Medication following baseline coronary angiography, n (%)
Acetylsalisylic acid 3376 (81.7) 1114 (79.9) 1638 (83.1) 624 (81.5) 0.05
Statins 3310 (80.1) 1064 (76.3) 1626 (82.5) 620 (80.9) <0.001
β-blockers 2994 (72.5) 970 (69.5) 1456 (73.9) 568 (74.2) 0.01
ACE inhibitors 858 (20.8) 243 (17.4) 403 (20.5) 212 (27.7) <0.001
Loop diuretics 447 (10.8) 127 (9.1) 182 (9.2) 138 (18.0) <0.001
Coronary revascularization following baseline coronary angiography, n (%)
Percutaneous coronary intervention 1348 (32.6) 432 (31.0) 663 (33.7) 253 (33.0) 0.26
Coronary artery bypass graft surgery 892 (21.6) 302 (21.6) 438 (22.2) 152 (19.8) 0.39
Biochemical markers
Creatinine (μmol/L) 92.6 (31.1) 92.5 (33.4) 93.0 (32.0) 91.8 (23.4) 0.34
eGFR (mL/min) 87.8 (17.3) 86.2 (17.7) 88.5 (16.6) 88.9 (17.8) <0.001
CRP (mg/L) 3.69 (7.17) 3.34 (7.93) 3.59 (6.67) 4.60 (6.85) <0.001
Glucose (mmol/L) 6.35 (2.40) 5.93 (2.24) 6.32 (2.28) 7.20 (2.79) <0.001
HbA1c (mmol/L) 6.22 (1.38) 6.12 (1.28) 6.18 (1.41) 6.51 (1.45) <0.001
Hemoglobin (g/dL) 14.2 (1.24) 13.9 (1.24) 14.4 (1.18) 14.4 (1.29) <0.001
ApoA1 (g/L) 1.32 (0.27) 1.37 (0.29) 1.30 (0.25) 1.27 (0.26) <0.001
ApoB (g/L) 0.90 (0.25) 0.87 (0.24) 0.91 (0.24) 0.93 (0.26) <0.001
Total cholesterol (mmol/L) 5.07 (1.17) 5.02 (1.14) 5.08 (1.18) 5.10 (1.19) 0.13
LDL cholesterol (mmol/L) 3.09 (1.03) 3.05 (1.02) 3.12 (1.00) 3.11 (1.10) 0.11
HDL cholesterol (mmol/L) 1.29 (0.38) 1.42 (0.43) 1.25 (0.34) 1.17 (0.32) <0.001
Triglycerides (mmol/L) 1.78 (1.22) 1.43 (0.90) 1.86 (1.28) 2.22 (1.39) <0.001
Lp(a) (mmol/L) 0.42 (0.39) 0.41 (0.39) 0.43 (0.39) 0.42 (0.39) 0.03
WENBIT intervention trial, n (%) 2560 (62.0) 797 (57.1) 1283 (65.1) 480 (62.7) <0.001
B6, n (% of WENBIT participants) 1275 (49.8) 394 (49.4) 657 (51.2) 224 (46.7) <0.01
Folate/B12, n (% of WENBIT participants) 1282 (50.1) 409 (51.3) 649 (50.6) 224 (46.7) 0.04

ACE, angiotensin converting enzyme; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, body mass index; CRP, c-reactive protein; eGFR, esitimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low density lipoprotein; Lp(a), lipoprotein (a).

aNormal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25–29.9 kg/m2) and obese (BMI ≥ 30 kg/m2).

bBased on between group differences calculated by one-way analysis of variance (ANOVA) for continuous variables and Chi squared test for categorical variables.

cMean (SD).

dIncludes DM type 1 and 2.

eSmokers included self-reported current smoking, those who quit smoking within <1 month and patients with plasma cotinine >85 ng/mL.

fPatients reported to have quit smoking > 1 month prior to inclusion.

gIncluded those reporting to have at least one 1st degree relative suffering from CAD before the age of 55 for men and 65 for women.

Borgeraas et al.

Borgeraas et al. BMC Cardiovascular Disorders 2014 14:68   doi:10.1186/1471-2261-14-68

Open Data